Form 4 for EW Edwards Lifesciences
Accepted 2024-05-06 00:00:00 ET · period of report 2024-05-03 · accession 0001225208-24-005701 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-05-06 | 2024-05-03+ | EW | Chopra Daveen | CVP, TMTT | F - Tax | $85.23 | -2,612 | 22.5K | -10% | -$222.6K |
| D | 2024-05-06 | 2024-05-04 | EW | Chopra Daveen | CVP, TMTT | M - OptEx | $0.00 | +4,713 | 27.2K | +21% | $0 |
| D | 2024-05-06 | 2024-05-04 | EW | Chopra Daveen | CVP, TMTT | M - OptEx | $0.00 | -4,713 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-04 | F | D | 2,321 | $85.25 | 24,851 | D | — | — | |
| 2 | Common | Common Stock | 2024-05-03 | F | D | 291 | $85.06 | 22,459 | D | — | — | |
| 3 | Common | Common Stock | 2024-05-04 | M | A | 4,713 | $0.00 | 27,172 | D | — | — | (F1) On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. |
| 4 | Derivative | Performance Rights | 2024-05-04 | M | D | 4,713 | $0.00 | 0 | D | — · 2024-05-04 to 2028-05-03 | 4,713 Common Stock | (F1) On May 4, 2021, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2024, the Compensation and Governance Committee of the Board of Directors determined that 117.11% of the target number of shares would vest as of May 4, 2024, and the actual number of shares vested are reflected on this Form 4. |